News & Events about Omeros Corporation.
Omeros Corporation (Nasdaq: OMER) today announced positive results from a pre-specified interim analysis of its ongoing Phase 1b clinical trial of OMS906, the companys lead MASP-3 inhibitor, in complement-inhibitor-nave adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare and...
Omeros Corporation (Nasdaq: OMER) today announced that it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to develop Omeros lead orally administered compound from its proprietary phosphodiesterase 7 (PDE7) program OMS527 for the...
Business Wire
2 months ago
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2022, on Monday, March 13, 2023, after the market closes. Omeros management will host a conference call and webcast that same day at...
Business Wire
3 months ago
Omeros Corporation (Nasdaq: OMER) today announced that Rayner Surgical, Inc. (Rayner) has paid the $200 million milestone payment due to Omeros under the Asset Purchase Agreement, dated December 1, 2021 (the Agreement), pursuant to which Omeros sold its ophthalmology product OMIDRIA to Rayner in...
Thinking about buying stock in AMC Entertainment, TAL Education, Omeros Corp, Acer Therapeutics, or Viking Therapeutics? Thinking about buying stock in AMC Entertainment, TAL Education, Omeros Corp, Acer Therapeutics, or Viking Therapeutics? PR Newswire NEW YORK, Dec. 23, 2022 NEW YORK, Dec. 23...